Osiris Therapeutics (OSIR) has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children. The approval marks the first time a manufactured stem cell product has been given regulatory clearance and the first therapy approved for the disease. Shares +14% AH
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/